Emerging data also link elevated IL-6 and IL-10 levels with increased PD-L1 expression and reduced cytotoxic T-cell activity in NSCLC, suggesting an intersection between inflammatory signaling and immune checkpoint regulation [17,25]. The gene discussed is IL6; the disease is non-small cell lung carcinoma.